EB-DUO-CAR-NK-CEA/GCC not checked
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ogeneic dual-target CAR-NK cells manufactured from cord blood-derived NK cells, genetically engineered to express a tandem (dual-binding) CAR, an IL-15 support element (e.g., membrane-bound IL-15 or IL-15/IL-15R fusion), and an inducible suicide switch”In the company’s words, NCT07589517 on ClinicalTrials.gov
- Tested for
- Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer, Colorectal Cancer Metastatic, Adenocarcinoma of Colon
- Main trialPhase 1/2
- “This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic colorectal cancer (CRC). Participants are assigned to one of three dual-target arms based on tumor antigen co-expression: (1) CEA+GUCY2C, (2) CEA+HER2, or (3) GUCY2C+HER2. Following dose escalation, the most suitable target pair (based on safety, feasibility, and early efficacy/biomarker signals) will be selected for dose expansion.”In the company’s words, NCT07589517 on ClinicalTrials.gov
Other drugs for Colorectal Cancer
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up2
- 14 Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 21 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 14 Mar 2027 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer | |
| Phase 1/2Recruiting | 21 Dec 2027 | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026